Abstract:Background: Studies have reported that 5hmC features in cell-free DNA (cfDNA) could serve as early warning biomarkers for the occurrence and progression of COVID-19, as well as myocardial injury. However, its roles in the occurrence and progression of acute coronary syndrome (ACS) following COVID-19 infection has not been fully studied. Methods: Firstly, we used the 5hmC-Seal technique to obtain genome-wide 5hmC profiles from plasma cfDNA of 24 ACS2N patients (individuals experiencing ACS onset within 2 months after COVID-19 infection), 28 ACS2W patients (individuals experiencing ACS onset beyond 2 months after COVID-19 infection), and 16 ACS patients (patients with ACS without COVID-19 infection). Secondly, we performed GO, KEGG analysis on the differentially expressed genes and identified a series of immune and inflammation related genes. Thirdly, the distribution of immune cells in different groups of patients was studied by immune infiltration analysis. Finally, we performed PPI network analysis on these genes to identify potential key target genes. Results: In this study, we firstly found that there was a significant difference in 5hmC levels between ACS2N patients and ACS patients, while the difference between ACS2W and ACS was not significant. Secondly, it was found that neutrophils were abnormally activated in the ACS2N group. Finally, a target gene phosphodiesterase 4D (PDE4D) was found to be highly expressed in the ACS2N group by PPI network analysis of the differential genes and validated with external datasets. Conclusions: Our study suggested that 5hmC markers extracted from plasma cfDNA could differentiate between ACS2N and ACS patients. In addition, we observed that neutrophils exhibited abnormal activation in ACS2N patients. Further analysis showed that COVID-19 infection may affect the occurrence and development of ACS by abnormally up-regulating PDE4D gene expression.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the role of 5 - hydroxymethylcytosine (5hmC) in patients with acute coronary syndrome (ACS) after COVID - 19 infection and its value as a potential biomarker. Specifically, the study focused on the following aspects: 1. **Changes in 5hmC levels**: By comparing the genome - wide distribution of 5hmC in plasma cell - free DNA (cfDNA) among different groups (i.e., patients with ACS occurring within 2 months after COVID - 19 infection (ACS2N), patients with ACS occurring more than 2 months after COVID - 19 infection (ACS2W), and ACS patients without COVID - 19 infection (ACS)), researchers explored the differences in 5hmC levels among these groups. 2. **Abnormal activation of immune cells**: The study found that neutrophils showed abnormal activation in the ACS2N group. This suggests that COVID - 19 infection may affect the occurrence and development of ACS by influencing the function of immune cells. 3. **Expression changes of key genes**: Through protein - protein interaction (PPI) network analysis, researchers identified that the PDE4D gene was highly expressed in the ACS2N group and was closely related to the activation of neutrophils. This indicates that PDE4D may be an important molecular mechanism in the development of ACS after COVID - 19 infection. ### Research background COVID - 19 not only increases the morbidity and mortality of ACS patients but may also affect the development of ACS through multiple mechanisms. These mechanisms include severe endothelial dysfunction, activation of the immune response, cytokine storm, hypoxemia, severe infection, changes in shear stress, and activation of the renin - angiotensin - aldosterone system (RAAS). In addition, the inflammatory mechanisms after COVID - 19 infection may lead to plaque rupture, form a pro - thrombotic environment, increase the risk of thrombosis, thereby affecting reperfusion and increasing the risk of in - stent thrombosis. ### Research methods 1. **Sample collection and grouping**: Researchers collected blood samples from ACS patients admitted to Peking University Third Hospital and divided the patients into three groups according to the time of COVID - 19 infection: ACS2N, ACS2W, and ACS. 2. **5hmC detection**: The 5hmC - Seal technique was used to perform genome - wide 5hmC profiling analysis on plasma cfDNA. 3. **Gene expression analysis**: Through GO and KEGG analyses, differentially expressed genes (DEGs) were identified, and their functions and pathways were analyzed. 4. **Immune cell infiltration analysis**: The CIBERSORT algorithm was used to analyze the infiltration of 22 types of immune cells. 5. **PPI network analysis**: A PPI network was constructed to identify key genes. ### Main findings 1. **Differences in 5hmC levels**: The study found that there were significant differences in 5hmC levels between the ACS2N group and the ACS group, while the difference between the ACS2W group and the ACS group was not significant. 2. **Abnormal activation of neutrophils**: In the ACS2N group, neutrophils showed abnormal activation. 3. **High expression of the PDE4D gene**: PPI network analysis showed that the PDE4D gene was highly expressed in the ACS2N group and was closely related to the activation of neutrophils. ### Conclusion This study preliminarily revealed the potential diagnostic value of 5hmC markers in ACS patients after COVID - 19 infection and found the important role of the PDE4D gene in this process. These findings provide new ideas for the early diagnosis and intervention of ACS after COVID - 19 infection.

5-hydroxymethylcytosine Epigenetic Markers in COVID-19-Associated Acute Coronary Syndrome: Insights into Neutrophil Activation and PDE4D Upregulation

Characteristics, prognostic determinants of monocytes, macrophages and T cells in acute coronary syndrome: protocol for a multicenter, prospective cohort study

Dendritic Cell-Derived Lncrna in Patients with Acute Coronary Syndrome

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Early Warning Biomarkers for COVID-19 Progression and Myocardial Injury

Genome-Wide Analysis of DNA Methylation and Acute Coronary Syndrome

5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA As Candidate Diagnostic and Predictive Biomarkers for Coronary Artery Disease

Genome-wide DNA Methylome Alterations in Acute Coronary Syndrome

Immune-related Chemotactic Factors Were Found in Acute Coronary Syndromes by Bioinformatics

Genome-wide DNA methylation profiling in blood reveals epigenetic signature of incident acute coronary syndrome

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA As Diagnostic and Predictive Biomarkers for Coronary Artery Disease

An Epigenome-Wide DNA Methylation Study of Patients with COVID-19.

Abstract 4135025: Inflammation-related 5-Hydroxymethylation Signatures As Markers for Clinical Presentations of Coronary Artery Disease

Differential Expression of Mir-140-3p and Its Potential Role During the Development of the Acute Coronary Syndrome.

High Proteoglycan Decorin Levels Are Associated with Acute Coronary Syndrome and Provoke an Imbalanced Inflammatory Response

Implications of cardiac markers in risk-stratification and management for COVID-19 patients

Dendritic cell‐derived lncRNAs in patients with acute coronary syndrome

Ceramides As Potential New Predictors of the Severity of Acute Coronary Syndrome in Conjunction with SARS-CoV-2 Infection

Predicting protective gene biomarker of acute coronary syndrome by the circRNA-associated competitive endogenous RNA regulatory network

5mC modification patterns provide novel direction for early acute myocardial infarction detection and personalized therapy

A neutrophil activation signature predicts critical illness and mortality in COVID-19

Systematic profiling of ACE2 expression in diverse physiological and pathological conditions for COVID-19/SARS-CoV-2